Oscillo Biosciences
Oscillo Biosciences is an early stage company whose mission is to preserve and restore memory and cognition in people with Alzheimer’s disease and related dementias.
Groundbreaking neuroscientific research on brain rhythms is offering new hope for this incurable disease. At Oscillo Biosciences, we are harnessing the power of music and synchronized light to stimulate brain rhythms, awakening memory and cognitive function previously thought to be permanently lost.
Alzheimer’s Disease is a Global Epidemic.
In the United States today, nearly 6 million people suffer from dementia due to Alzheimer’s disease. For these people, what began with mild memory loss and confusion has progressively worsened, and will eventually leave them unable to carry on a conversation or perform simple tasks. In time, they will require around-the-clock care. The effects are as devastating for families and caregivers as they are for patients.
Alzheimer’s disease is the sixth leading cause of death in America. And despite billions spent on research and pharmaceutical interventions, there is no cure.
The number of cases is projected to more than double to 6 million in the next 30 years.
12 million people suffer from Mild Cognitive Impairment, a precursor to Alzheimer’s dementia.
25 million people have preclinical Alzheimer’s disease—the biomarkers are there, but symptoms have not yet appeared.
.jpg)
Looking Beyond Pharmaceuticals
At Oscillo Biosciences, we are approaching Alzheimer’s disease with fresh eyes and ears.
SynchronyGamma is our patented non-invasive, non-pharmaceutical therapy that marries music and light to restore disrupted brain rhythms, memory, and cognition in patients living with Alzheimer’s disease.
Recognized and supported by the National Science Foundation, SynchronyGamma is the only intervention that combines the therapeutic effects of music with synchronized light to stimulate Gamma- and Theta-frequency brain waves, to restore and preserve memory and cognition.